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Summary
Methods and results: This study included 68 patients (47 men, 21 women, mean
age 69 years) in whom atrial ﬁbrillation (AF) recurred immediately after electrical
cardioversion (EC) was performed with no antiarrhythmic drugs. After administra-
tion of cibenzoline (Cib, 70mg) or pilsicainide (Pil, 50mg) on a randomized basis,
all patients again underwent EC at the same energy as that prior to administra-
tion of antiarrhythmic drugs. We compared the efﬁcacy of Cib (n = 35) and Pil
(n = 33), and examined factors affecting successful cardioversion in patients treated
with Cib. These patients were divided into a successful group (Group A) and an
unsuccessful group (Group B). The success rate of EC at the same energy after
intravenous Cib administration (77%) was signiﬁcantly greater than that after intra-
venous Pil administration (42%) (p < 0.01). In patients treated with Cib, AF duration
was signiﬁcantly greater in Group B (55.8± 48.2 h) than in Group A (29.1± 17.0 h)
(p < 0.05). Plasma concentrations of atrial natriuretic peptide (ANP) during AF and
the ratio of ANP level during AF to that during sinus rhythm were also signiﬁcantly
greater in Group A (110.9± 69.7 pg/ml and 3.9± 2.8, respectively) than in Group B
(58.2± 36.1 pg/ml and 1.8± 0.9, respectively) (both, p < 0.05). In patients treated
with Pil, AF duration was also signiﬁcantly greater in Group B (59.7± 44.6 h) than
in Group A (19.6± 21.7 h) (p < 0.05), and the ratio of ANP level during AF to that
during sinus rhythm was signiﬁcantly greater in Group A (3.5± 2.6) than in Group B
(1.7± 0.9) (p < 0.05).
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Conclusions: In patients with AF previously refractory to conventional EC, intravenous
Cib administration was more effective in restoring sinus rhythm with EC than intra-
venous Pil administration. The capacity of ANP secretion during AF tachycardia may
be a predictive indicator for the prevention of AF recurrence in electrically remodeled
atria.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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Introduction
There have been reports that the maintenance of
sinus rhythm for a long period in patients with
paroxysmal and persistent atrial ﬁbrillation (AF)
improved not only subjective symptoms but also
exercise tolerance [1] and prognosis in those with
heart failure [2,3]. There are two methods of
restoring normal sinus rhythm in patients with
AF—–pharmacological and electrical cardioversion
(EC), the latter of which has a higher success
rate. In 25% of those undergoing the electrical
procedure, however, cardioversion was impossi-
ble or unsuccessful due to immediate recurrence
of AF after restoration of sinus rhythm [4],
designated as immediate reinitiation of atrial ﬁb-
rillation (IRAF) [5]. It is considered that a high
rate of conversion to sinus rhythm would play a
key role in rhythm control therapy in patients
with AF.
Cibenzoline (Cib) is considered to have a phar-
macological action that blocks sodium, potassium,
and calcium channels as a multi-channel blocker,
whereas pilsicainide (Pil) is considered to block
only the sodium channel [6]. It would be expected,
Fig. 1 Flow diagram showing the outcome of 253 patients w
ﬁbrillation.
u
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oherefore, that the preventive effect of antiar-
hythmic drugs varies with the development of
lectrically remodeled atria.
In this study, we evaluated the effect of EC foll-
wing intravenous antiarrhythmic drugs therapy in
atients with lone AF in whom sinus rhythm was
ot restored by conventional EC without antiarry-
hmic drugs. We also examined the clinical proﬁles
f patients in whom EC was successful following
ntravenous Cib therapy.
ubjects
ubjects were recruited from June 2003 to
ugust 2007, and were selected from among 253
atients with lone paroxysmal and persistent AF
ho visited our hospital during that period. The
owchart of patients appears in Fig. 1. Seventy
atients (28%) received no antiarrhythmic drugs and
everted to AF immediately following supraventric-ho underwent EC. IRAF, immediate reinitiation of atrial
lar extrasystole after EC in a total of 253 patients
ho underwent EC. In two of these patients, AF
onverted to sinus rhythm after the administration
f intravenous Cib or Pil therapy. The remaining
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ation. The success rate of EC and clinical proﬁles ofrandomized study on the efﬁcacy of intravenous
8 patients were enrolled in this study (47 males;
1 females, mean age 69 years, age range 53—80).
ll patients had conﬁrmed immediate recurrence
f AF after the restoration of sinus rhythm via
C on electrocardiogram (ECG) monitoring. AF was
stablished according to clinical symptoms such as
alpitations with the detection of AF on ECG record-
ng.
All patients underwent chest X-ray exami-
ation, ECG recording, exercise ECG testing,
chocardiography, and brain CT scanning before
he initiation of antiarrhythmic therapy. Three
atients had underlying pulmonary diseases such
s healed tuberculosis (n = 1), bronchial asthma
n = 1), or chronic bronchitis (n = 1). Those with
ongestive heart failure, left ventricular ejection
raction <40% as determined by echocardiography,
radycardias <40 beats/min, severe intraventricu-
ar conduction disturbance, severe liver or renal
ysfunction, and the use of ß-blockers or L-type cal-
ium antagonists were excluded. Every patient gave
ritten informed consent prior to participation in
his study.
ethods
rotocols for cardioversion and
ntiarrhythmic drugs therapy
C for patients with paroxysmal and persistent AF
as divided into two approaches according to the
uration of arrhythmia. For patients in whom AF
asted for less than 48 h after occurrence, EC was
ttempted immediately after the administration of
ntravenous thiopental (2—5mg/kg) for anesthesia.
or those in whom AF lasted for more than 48 h after
ccurrence, the absence of intracardiac thrombus
r spontaneous echo contrast within the left atrium
as conﬁrmed on transesophageal echocardiogra-
hy, and EC was attempted after the administration
f intravenous heparin (100 IU/kg) [7]. If the pres-
nce of intracardiac thrombus or spontaneous echo
ontrast was observed, anticoagulant therapy with
arfarin was administered for 3 weeks before and
or at least 4 weeks after EC [8]. The dose of
arfarin was set so as to obtain an international
ormalized ratio (INR) between 1.6 and 2.6. EC
as performed with the patients having fasted
nd under adequate anesthesia. With an anterior-
ateral (ventricular apex and right infraclavicular)
addle position, cardioversion was performed with
n average energy requirement of 248± 61 J (range
50—350 J). The initial test of the cardioversion
nergy used 150 J and if it was unsuccessful, a
50—350 J shock was then tried. Cardioversion was
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iscontinued in cases in whom sinus rhythm was
ot entirely restored due to a high atrial deﬁbril-
ation threshold (Fig. 2, II-A). On the other hand,
hen AF recurred within a few seconds or min-
tes following supraventricular extrasystole after
he restoration of sinus rhythm by EC (IRAF), Cib
70mg) or Pil (50mg) selected randomly by an enve-
ope method was administered intravenously over
min, and all patients underwent EC at the same
nergy level as that before antiarrhythmic drugs
Fig. 2, II-B). After EC, ECG recordings were mon-
tored for at least 3 h to determine whether sinus
hythm was maintained without recurrence of AF.
f sinus rhythm was maintained, oral antiarrhyth-
ic drugs therapy was instituted to prevent the
ecurrence of AF.
We evaluated the success rate in patients under-
oing EC after intravenous Cib or Pil therapy on
randomized basis. These patients were classi-
ed into two groups according to their response
o EC after intravenous Cib and Pil therapy:
roup A consisted of patients in whom sinus
hythm was maintained without recurrence of
F; Group B consisted of patients in whom AF
ecurred despite intravenous antiarrhythmic ther-
py. We also compared clinical proﬁles between
he two groups. Atrial natriuretic polypeptide
ANP) was measured in a supine position at rest
rom a vein in the upper extremities during AF
nd sinus rhythm before the initial episode of
aroxysmal and persistent AF. Verbal or written
nformed consent regarding the therapeutic strat-
gy employed in this study was obtained from all
atients
eﬁnition and statistical analysis
aroxysmal AF was deﬁned as AF terminating spon-
aneously within 7 days after occurrence. Persistent
F was deﬁned as AF converting to sinus rhythm
y pharmacological and EC without spontaneous
estoration. AF duration was the period from the
pisode of AF to the time of EC and suffering
eriod was the duration from the initial episode
f AF to the time of the initial visit to our hospi-
al. Hypertension was deﬁned as blood pressures
reater than 140mmHg at systole and 90mmHg at
iastole.
All data are shown as mean± one standard devi-atients were compared between the groups with
he uses of one-way ANOVA for continuous vari-
bles and Chi-square test for categorical variables.
< 0.05 was considered as a statistical signiﬁ-
ance.
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Fig. 2 Demonstration of monitoring electrocardiogram recording prior to and after EC in patients with lone paroxysmal
and persistent atrial ﬁbrillation. (I) Successful cardioversion. (II-A) Unsuccessful cardioversion due to high deﬁbril-
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Tlation threshold. (II-B) Unsuccessful cardioversion due
seconds following supraventricular extrasystole after res
DC, direct-current cardioversion.
Results
Effect of intravenous antiarrhythmic drugs
therapy
Thirty-ﬁve patients were administered Cib, and the
remaining thirty-three patients were administered
Pil as intravenous antiarrhythmic drugs therapy
on a randomized basis. There was no signiﬁcant
difference in body weight, duration of AF, suffer-
ing period, end-diastolic left ventricular dimension
(LVDd), left atrial dimension (LAD), or left ven-
tricular ejection fraction (LVEF) as determined by
echocardiography, number of EC before intravenous
antiarrhythmic therapy, plasma concentration of
ANP during sinus rhythm and atrial ﬁbrillation, or
the ratio of ANP level during AF to that during sinus
rhythm between the two groups (Table 1). Twenty-
seven patients (77%) had successful EC at the same
energy after intravenous Cib therapy (77%), and
only 14 patients had successful cardioversion after
intravenous Pil therapy (42%). EC was signiﬁcantly
more successful in patients treated with Cib than
in those with Pil (p < 0.01). No patients showed
adverse effects after antiarrhythmic drug therapy
or had any occurrence of thromboembolism.
P
g
(
fmediate recurrence of atrial ﬁbrillation within a few
ion of sinus rhythm. SVE, supraventricular extrasystole;
omparison of clinical proﬁles between
uccessful and unsuccessful groups
hirty-ﬁve patients treated with intravenous Cib
herapy were divided into a successful group (Group
, n = 27) and an unsuccessful group (Group B, n = 8).
here was no signiﬁcant difference in age, body
eight, gender, percentages of patients with coro-
ary risk factors and alcohol habits, distribution of
nderlying pulmonary disease, or past history of
hromboembolism between the two groups. There
as also no signiﬁcant difference in LVDd, LAD, or
VEF as determined by transthoracic echocardiog-
aphy, or plasma concentration of ANP during sinus
hythm. AF duration and AF morbidity were signif-
cantly higher in Group B than in Group A (p < 0.05,
< 0.01, respectively). Plasma concentrations of
NP during AF and the ratio of ANP level during
F to that during sinus rhythm were also signiﬁ-
antly higher in Group A than in Group B (p < 0.05;
able 2).
Thirty-three patients treated with intravenous
il therapy were also divided into a successful
roup (Group A, n = 14) and an unsuccessful group
Group B, n = 19). There was no signiﬁcant dif-
erence in age, body weight, gender, percentages
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Table 1 Comparison of clinical proﬁles between two patient groups treated with cibenzoline and pilsicainide
therapy
Cibenzoline (n = 35) Pilsicainide (n = 33) p-Value
Body weight (kg) 65.2 ± 10.9 63.7 ± 11.1 N.S.
Duration of AF (h) 38.6 ± 27.2 41.9 ± 30.6 N.S.
Suffering period (months) 31.9 ± 35.9 34.5 ± 39.3 N.S
LVDd (mm) 47.8 ± 4.2 47.4 ± 3.8 N.S.
LAD (mm) 37.3 ± 5.6 37.6 ± 6.1 N.S.
LVEF (%) 69.2 ± 8.4 70.5 ± 6.9 N.S.
ANP during AF (pg/ml) 31.8 ± 14.6 32.2 ± 17.4 N.S.
ANP during SR (pg/ml) 85.3 ± 51.7 79.8 ± 62.4 N.S.
Ratio of ANP (AF/SR) 2.4 ± 1.6 2.5 ± 1.7 N.S.
Number of EC 1.5 ± 0.6 1.7 ± 0.6 N.S.
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f patients with coronary risk factors and alco-
ol habits, distribution of underlying pulmonary
isease, past history of thromboembolism, and
VDd, LAD, or LVEF as determined by transtho-
acic echocardiography, or plasma concentrations
f ANP during sinus rhythm and AF between the
wo groups. AF duration and AF morbidity were
igniﬁcantly higher in Group B than in Group A
both, p < 0.05). The ratio of ANP level during
F to that during sinus rhythm was also signiﬁ-
antly higher in Group A than in Group B (p < 0.05,
able 3).
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Table 2 Comparison of clinical proﬁles between success
cibenzoline therapy
A-group (n = 27) B-group (n = 8)
Age (years) 69.2± 9.9
Body weight (kg) 64.6± 11.4
♂: ♀ 19:8
Smoking 6 (22.2%)
Hypertension 10 (37.0%)
Diabetes mellitus 6 (22.2%)
Hyperlipidemia 3 (11.1%)
Alcohol 12 (44.4%)
Organic pulmonary disease 2 (7.4%)
Thromboembolism 5 (18.5%)
Duration of AF (h) 29.1± 17.0
Suffering periods (months) 18.9± 22.8
LVDd (mm) 47.7± 5.8
LAD (mm) 37.5± 5.1
LVEF (%) 67.4± 13.9
ANP during SR (pg/ml) 33.9± 19.9
ANP during AF (pg/ml) 110.9± 69.7
Ratio of ANP (AF/SR) 3.9± 2.8
Continuous values are mean± S.D. Values in parenthesis are given
after intravenous cibenzoline therapy. B-group, patients in whom E
atrial ﬁbrillation; LVDd, left ventricular end-diastolic dimension; LAD
ANP, atrial natriuretic peptide; SR, sinus rhythm.lypeptide; AF, atrial ﬁbrillation; SR, sinus rhythm; LVDd, left
left ventricular ejection fraction; EC, electrical cardioversion.
iscussion
F recurs within a month after cardioversion
n many patients, and recent day-to-day post-
onversion studies have established several pat-
erns of recurrence [9]. In some cases, there is
omplete failure of EC due to a high atrial deﬁbrilla-
ion threshold. In others, AF reappears within a few
econds or minutes after a period of sinus rhythm
5,9]. According to the ACC/AHA/ESC guidelines
10], it has been reported that adequate antiar-
hythmic drug therapy prior to EC can enhance the
ful and unsuccessful groups in patients treated with
p-Value
66.7± 6.4 N.S.
65.8± 10.7 N.S.
6:2 N.S.
2 (25.0%) N.S.
4 (50.0%) N.S.
1 (12.5%) N.S.
2 (25.0%) N.S.
4 (50.0%) N.S.
1 (12.5%) N.S.
1 (12.5%) N.S.
55.8± 48.2 <0.05
68.0± 55.5 <0.01
48.4± 3.1 N.S.
37.2± 6.2 N.S.
72.2± 6.2 N.S.
30.2± 11.2 N.S.
58.2± 36.1 <0.05
1.8± 0.9 <0.05
as percentage. A-group, patients in whom EC was successful
C was unsuccessful after intravenous cibenzoline therapy. AF,
, left atrial dimension; LVEF, left ventricular ejection fraction;
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Table 3 Comparison of clinical proﬁles between successful and unsuccessful groups in patients treated with
pilsicainide therapy
A-group (n = 14) B-group (n = 19) p-Value
Age (years) 69.7± 10.2 70.3± 8.4 N.S.
Body weight (kg) 64.9± 10.1 62.3± 12.1 N.S.
♂: ♀ 9:5 13:6 N.S.
Smoking 4 (28.6%) 5 (26.3%) N.S.
Hypertension 4 (28.6%) 8 (42.1%) N.S.
Diabetes mellitus 2 (14.3%) 4 (21.1%) N.S.
Hyperlipidemia 2 (14.3%) 3 (15.7%) N.S.
Alcohol 7 (50.0%) 9 (47.3%) N.S.
Organic pulmonary disease 1 (7.1%) 1 (5.3%) N.S.
Thromboembolism 3 (21.4%) 2 (10.5%) N.S.
Duration of AF (h) 19.6± 21.7 59.7± 44.6 <0.05
Suffering periods (months) 11.4± 24.7 51.2± 39.7 <0.05
LVDd (mm) 46.8± 6.3 47.1± 5.1 N.S.
LAD (mm) 36.5± 5.7 37.4± 5.9 N.S.
LVEF (%) 70.3± 8.8 69.6± 10.7 N.S.
ANP during SR (pg/ml) 27.8± 17.6 29.7± 16.9 N.S.
ANP during AF (pg/ml) 96.5± 58.4 51.7± 32.4 N.S
Ratio of ANP (AF/SR) 3.5± 2.6 1.7± 0.9 <0.05
Continuous values are mean± S.D. A-group, patients in whom EC was successful after intravenous pilsicainide therapy. B-group,
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effect of conversion to sinus rhythm and prevent
immediate recurrences of AF. In order to obtain
a high success rate for EC, it therefore appears
appropriate to maintain therapeutic plasma drug
concentrations at the time of cardioversion and
for a few weeks thereafter. In available data [10],
antiarrhythmic drugs were administered orally prior
to cardioversion. However, treatment is required
for a period from several days to several weeks
to obtain therapeutic plasma drug concentrations
with oral administration of antiarrhythmic drugs.
If AF lasted for more than 48 h after occurrence,
concomitant use of anticoagulant therapy is con-
sidered to be necessary [9], and the efﬁcacy of
antiarrhythmic drugs in preventing recurrence of
AF is limited due to the development of electri-
cally remodeled atria [11,12]. Conversely, if early
EC is performed after intravenous administration
of antiarrhythmic drugs, the subsequent long-term
efﬁcacy in preventing recurrence of AF may be
enhanced. The previous study demonstrated that
intravenous class III antiarrhythmic drugs, such as
ibutilide or sotalol, facilitated conversion to sinus
rhythm in patients with AF, which is resistant to con-
ventional EC [13,14]. Unfortunately, intravenous
ibutilide or sotalol therapy is not available in Japan.
It has been unclear whether intravenous Cib or
Pil therapy, which is regarded as class I antiar-
rhythmic drugs and is currently available in Japan,
prior to EC facilitates conversion to sinus rhythm
r
c
e
ae therapy. AF, atrial ﬁbrillation; LVDd, left ventricular end-
r ejection fraction; ANP, atrial natriuretic peptide; SR, sinus
n those with AF. This study included only patients
n whom AF recurred within a few seconds or min-
tes following supraventricular extrasystole after
he restoration of sinus rhythm by means of EC.
he success rate of EC at the same energy after
ntravenous Cib therapy was 77%, and that rate was
onsidered to be high relatively compared with Pil
herapy.
Cib is considered to have pharmacological
ffects on atrial and ventricular myocardium,
ncluding blocking of sodium channels, potas-
ium channels, calcium channels, and muscarinic
eceptors [15]. In relation to its potassium channel-
locking effects, there have been reports showing
hat Cib blocks rapid (Ikr) as well as slow (Iks)
elayed rectiﬁer potassium currents, inward potas-
ium current (Ikl), and acetylcholine-activated
otassium current (IKach) [15,16]. On the other
and, Pil is considered to have only pure sodium
hannel-blocking effects [6]. After prolonged rapid
trial pacing in an experimental animal model,
own-regulation in L-type calcium current (IcaL) and
odium current (INa) with up-regulation of inward
ectiﬁer potassium current (Ik1), acetylcholine-
ctivated K current (IKach), and delayed rectiﬁer
current (IKS) in atrial myocardium have beeneported [17—21]. This time-course change in ion
hannels described the above results in a short-
ned effective refractory period of atrial muscle
nd shortened excitable wavelengths according to
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[randomized study on the efﬁcacy of intravenous
he reduction in conduction velocity. Eventually,
n arrhythmogenic substrate in which AF can be
asily induced and perpetuated is developed. In
his study, we suggest that the high success rate in
atients treated with intravenous Cib therapy prior
o EC was induced by its pharmacological action
uch as blocking of Ik1, IKach, and Iks which were
p-regulated in electrically remodeled atria.
In patients with AF, we have reported that
he effect of pharmacological conversion to sinus
hythm treated with intravenous Cib and Pil ther-
py was closely related to the capacity of ANP
ecretion [22]. In the present study, we have also
ound that plasma concentration of ANP during AF
nd the ratio of ANP level during AF to that during
inus rhythm were signiﬁcantly greater in patients
ith successful EC than in those where the proce-
ure was unsuccessful. These results suggest that
ntravenous Cib and Pil therapy prior to EC may be
ffective in patients who have less degeneration in
trial myocytes as estimated by the capacity of ANP
ecretion.
imitations
n this study, we did not evaluate the refrac-
ory period and conduction velocity in atrial
yocardium before intravenous antiarrhythmic
herapy according to AF refractory to EC, and could
ot elucidate the mechanism by which the recur-
ence of AF was prevented after EC. However, this
tudy included only patients in whom AF recurred
ithin a few seconds or minutes following supraven-
ricular extrasystole after the restoration of sinus
hythm by means of EC. There was a methodological
imitation for evaluating changes in the refractory
eriod and conduction velocity before and after
harmacological intervention. The spectral analysis
f surface ECG was not also examined before and
fter intravenous Cib or Pil therapy. This approach
ay be available to analyze the mechanism of
uccessful EC after intravenous antiarrhythmic
herapy.
onclusions
n patients with lone paroxysmal and persistent AF
efractory to conventional EC, intravenous Cib ther-
py was effective in restoring sinus rhythm with
C. Electrical remodeling in the atrial myocardium
eems to be related to the efﬁcacy of intravenous
ib therapy prior to EC, and the capacity of ANP
ecretion may be a predictive indicator for prevent-
ng the recurrence of AF.
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